ViroPharma Drops on FTC Probe, Generic Drug Rival
Antibiotic maker ViroPharma (VPHM) is making news today and none of it is good for the company’s investors. Not only does ViroPharma now face generic competition for its lead product Vancocin the US Federal Trade Commission is investigating whether the company “engaged in unfair methods of competition” when it sold the powerful antibiotic. Watson Pharmaceuticals (WPI) got the green light to sell generic Vancocin in the US despite ViroPharma’s efforts to block approval. Shares of ViroPharma fell 17% to $23.84 in midday trading Tuesday. The stock is still up more than 20% over the past six months. Watson fell ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here